NEW YORK (TheStreet) -- Achillion Pharmaceuticals (ACHN) surged to a 52-week high of $9.94 on Friday after the company announced its experimental hepatitis C drug ACH-3102 cured all patients in a mid-stage trial.

Interim results from the trial showed no detectable traces of the hepatitis C virus in 12 patients who took the drug in combination with Gilead Sciences' (GILD) Sovaldi, also known as sofosbuvir, four weeks after treatment completion. Achillion announced it would start treatment on 12 additional patients for six weeks with a once-daily dose of the two drugs.

The trial did include an older hepatitis C drug called ribavirin, which had side effects including rashes and anemia.